MPNs

Latest News

Newer JAK Inhibitors Aid in Cytopenia Management for High-Risk Myelofibrosis
Newer JAK Inhibitors Aid in Cytopenia Management for High-Risk Myelofibrosis

July 10th 2024

During a Case-Based Roundtable® event, Kristen Pettit, MD, discussed the use of pacritinib and momelotinib in cytopenic myelofibrosis in the second article of a 2-part series.

Predicting Polycythemia Vera Progression With Novel Indicators and Biomarkers
Predicting Polycythemia Vera Progression With Novel Indicators and Biomarkers

June 27th 2024

Ruxolitinib Treatment in Myelofibrosis Still Effective, Regardless of Anemia
Ruxolitinib Treatment in Myelofibrosis Still Effective, Regardless of Anemia

June 21st 2024

Challenging Disease Features of Myelofibrosis Lead to Use of JAK Inhibitors
Challenging Disease Features of Myelofibrosis Lead to Use of JAK Inhibitors

June 17th 2024

MOST Study Shows High Rates of Disease Progression in Low/Intermediate-Risk MF Over 4 Years
MOST Study Shows High Rates of Disease Progression in Low/Intermediate-Risk MF Over 4 Years

June 14th 2024